Cardiac Science raises $8.7 million:
This article was originally published in Clinica
Executive Summary
Cardiac Science has raised $8.7 million through a private placement. The Irvine, California-based company claims it has developed the only external defibrillator that continuously monitors in-hospital patients at risk of sudden cardiac arrest. If necessary, the product administers a shock within seconds, without the aid of hospital staff. The company will use the proceeds for the global marketing of its Powerheart ECD, which it plans to launch this quarter.
You may also be interested in...
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.